

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Stanley Wiegand et al.

**Serial No.:** to be assigned

**Group:** Not Yet Assigned

**Filing Date:** Concurrently herewith

**Examiner:** Not Yet Assigned

**Title:** Methods of Identifying Modulators of NMUR2-Mediated Activity

Commissioner for Patents  
US Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:


- [X]** Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Att. Docket No.: REG 980A  
USSN: to be assigned  
File Date: Concurrently herewith  
Information Disclosure Statement

### **Fees**

There is no fee required for the filing of this Information Disclosure Statement.  
In the event there is a fee inadvertently omitted, Applicants hereby authorizes the fee to  
be charge to Deposit Account number 18-0650.

Respectfully submitted

  
\_\_\_\_\_  
Valeta Gregg  
Reg. No. 35,127  
Attorney for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 980A  
Serial No. : to be assigned  
Applicant: : Stanley J. Wiegand et al.  
Date Filed : Concurrently herewith  
For : METHODS OF IDENTIFYING  
MODULTORS OF NMUR2-MEDIATED  
ACTIVITY  
  
Examiner : Not Yet Known  
Group Art Unit : Not Yet Known

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	6,461,836	Oct. 8, 2002	Elshourbagy et al.	_____	Apr. 10, 2000

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation</u> <u>Yes</u> <u>No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner  
Initials

\_\_\_\_\_ Raddatz, et al., J. Biol. Chem. Vol. 275, No. 42, pp. 32452-32459  
                  (2000)

\_\_\_\_\_ Howard, et al., Nature, vol. 406, pp. 71-74, (2000)


\_\_\_\_\_ Shan et al., J. Biol. Chem., Vol. 275, No. 50, pp 39482-39486, (2000)

EXAMINER  
CONSIDERED

DATE

EXAMINER:           Initial if citation considered, whether or not citation is in  
                          conformance with MPEP 609; draw line through citation if  
                          not in conformance and not considered. Include copy of this  
                          form with next communication to applicant.

Respectfully submitted,

By:   
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400